Darinaparsin

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

...atment of multiple myeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) gene expression profiling data that furt...y study is not yet evaluable (3 patients treated). darinaparsin has been well tolerated and no clinically relevant...ntinued benign safety profile, we are hopeful that darinaparsin will find a place in our treatment armamentarium."...

Darinaparsin in other areas

Understanding ZIO-101 (Darinaparsin):IMF

The activity of Darinaparsin against cul- tured myeloma cells and transplanted tumors ... Darinaparsin represents a new class of small. molecule cancer therapy ...

Leukemia Journal Publishes Results from Darinaparsin Study | Reuters

Study Suggests Potentially Broader Therapeutic Spectrum for Darinaparsin than Inorganic Arsenic NEW YORK--(Business Wire)-- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) ...

ZIOPHARM Oncology, Inc. - Leukemia Journal Publishes Results from ...

Darinaparsin than Inorganic Arsenic ... The study showed that darinaparsin is highly active in vitro against certain ... Darinaparsin induces cell cycle arrest ...

ZIOPHARM Oncology, Inc. - ZIOPHARM Presents Darinaparsin Molecular ...

In contrast to ATO, darinaparsin is not a substrate for the multi-drug ... In addition, darinaparsin induces cell death despite overexpression of MRP1/ABCC1. ...

Leukemia Journal Publishes Results From Darinaparsin Study

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance ...

News: Leukemia Journal Publishes Results from Darinaparsin Study.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line ...